← All stocks

OCULAR THERAPEUTIX, INC

OCUL Mostly scheduled

CIK 0001393434 #1892 in the set updated 17 Sep 2026

Bought (1 mo)

$0.00

out of their own pocket, the only kind of buying there is

Sold (1 mo)

$333.08K

$321.83K on a plan · $0.00 straight out of an exercise

Sold at will

$11.25K

1 of 5 sales

Net

−$333.08K

−$11.25K against sales at will

By person

17 insiders · 5 transactions

Insider

Role

Bought

Sold

Net

Holding

Of company

Worth

Change

Dugel Pravin

See Remarks

—

$233.16K (1) scheduled

−$233.16K

3,270,332

1.49%

$33.49M

+302.5%

Heier Jeffrey S.

Chief Scientific Officer

—

$35.53K (1) scheduled

−$35.53K

318,326

0.1449%

$3.26M

+82.3%

Kaiser Peter

Chief Development Officer

—

$32.69K (1) scheduled

−$32.69K

264,378

0.1204%

$2.71M

+122.9%

Nayak Sanjay

Chief Strategy Officer

—

$20.45K (1) scheduled

−$20.45K

326,898

0.1488%

$3.35M

+85.5%

Notman Donald

Chief Operating Officer

—

$11.25K (1)

−$11.25K

366,529

0.1669%

$3.75M

+70.5%

Waheed Nadia

Chief Medical Officer

—

300,079

0.1366%

$3.07M

+111.8%

LINDSTROM RICHARD L MD

Director

—

260,933

0.1188%

$2.67M

+60.4%

Saroj Namrata

Chief Business Officer

—

254,620

0.1159%

$2.61M

+26.4%

Meyers Steve Lawrence

Chief Commercial Officer

—

217,628

0.0991%

$2.23M

+42.5%

Anderman Todd

Chief Legal Officer

—

152,468

0.0694%

$1.56M

—

Robinson David Wayne

Global CCO

—

136,000

0.0619%

$1.39M

—

Warden Charles M

Director

—

100,464

0.0457%

$1.03M

+38.6%

Robins Jason Shand

Chief Financial Officer

—

68,097

0.0310%

$697.31K

+29.3%

Williams Leslie J.

Director

—

65,433

0.0298%

$670.03K

+74.8%

Graves Adrienne L

Director

—

64,000

0.0291%

$655.36K

+77.8%

RAINES MERILEE

Director

—

60,933

0.0277%

$623.95K

+85.0%

Hong Seung Suh

Director

—

60,933

0.0277%

$623.95K

+85.0%

Individual transactions

Insider

Date

Role

Action

Price

Amount

Notman Donald

31 Aug 2026

Chief Operating Officer

Sell

1,099

$10.24

$11.25K

Show all 5 transactions →

What was left out

Form 4 filings counted 5

Amendments (4/A) skipped 0

Filings about a different issuer 0

Unreadable filings 0

Joint filings 0

Sales on a Rule 10b5-1 plan 4

Sales straight out of an exercise 0

Sales at will 1

Transactions with no price 0

Shares from compensation/vesting 100,184

History held since 8 Nov 2016